Log in

Axonics Modulation Technologies Stock Price, News & Analysis (NASDAQ:AXNX)

$20.44
-0.04 (-0.20 %)
(As of 10/21/2019 04:25 AM ET)
Today's Range
$20.16
Now: $20.44
$20.93
50-Day Range
$20.07
MA: $28.34
$36.02
52-Week Range
$11.95
Now: $20.44
$43.37
Volume133,249 shs
Average Volume345,378 shs
Market Capitalization$582.95 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Axonics Modulation Technologies, Inc., a medical technology company, focuses on the design, development, and commercialization of sacral neuromodulation solutions (SNM) solutions. The SNM therapy is primarily used to treat patients with overactive bladder, including urinary urgency incontinence and urinary urgency frequency, fecal incontinence, and urinary retention. Its proprietary r-SNM System delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of urinary and fecal dysfunction. The company was formerly known as American Restorative Medicine, Inc. and changed its name to Axonics Modulation Technologies, Inc. in August 2013. Axonics Modulation Technologies, Inc. was founded in 2012 and is based in Irvine, California.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AXNX
CUSIPN/A
CIKN/A
Phone949-396-6322

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$710,000.00
Book Value$5.15 per share

Profitability

Net Income$-32,480,000.00
Net Margins-1,515.61%

Miscellaneous

Employees87
Market Cap$582.95 million
Next Earnings Date12/10/2019 (Estimated)
OptionableNot Optionable

Receive AXNX News and Ratings via Email

Sign-up to receive the latest news and ratings for AXNX and its competitors with MarketBeat's FREE daily newsletter.


Axonics Modulation Technologies (NASDAQ:AXNX) Frequently Asked Questions

What is Axonics Modulation Technologies' stock symbol?

Axonics Modulation Technologies trades on the NASDAQ under the ticker symbol "AXNX."

How were Axonics Modulation Technologies' earnings last quarter?

Axonics Modulation Technologies Inc (NASDAQ:AXNX) posted its quarterly earnings results on Monday, August, 5th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.51) by $0.17. The company earned $1.49 million during the quarter, compared to analysts' expectations of $1.04 million. Axonics Modulation Technologies had a negative return on equity of 59.67% and a negative net margin of 1,515.61%. The firm's quarterly revenue was up 12300.0% compared to the same quarter last year. View Axonics Modulation Technologies' Earnings History.

When is Axonics Modulation Technologies' next earnings date?

Axonics Modulation Technologies is scheduled to release their next quarterly earnings announcement on Tuesday, December 10th 2019. View Earnings Estimates for Axonics Modulation Technologies.

What price target have analysts set for AXNX?

7 equities research analysts have issued 12 month target prices for Axonics Modulation Technologies' stock. Their forecasts range from $14.92 to $47.00. On average, they expect Axonics Modulation Technologies' stock price to reach $38.27 in the next year. This suggests a possible upside of 87.3% from the stock's current price. View Analyst Price Targets for Axonics Modulation Technologies.

What is the consensus analysts' recommendation for Axonics Modulation Technologies?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axonics Modulation Technologies in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Axonics Modulation Technologies.

Has Axonics Modulation Technologies been receiving favorable news coverage?

Press coverage about AXNX stock has trended somewhat positive on Monday, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Axonics Modulation Technologies earned a daily sentiment score of 0.8 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Axonics Modulation Technologies.

Are investors shorting Axonics Modulation Technologies?

Axonics Modulation Technologies saw a increase in short interest in September. As of September 15th, there was short interest totalling 2,680,000 shares, an increase of 8.1% from the August 15th total of 2,480,000 shares. Based on an average trading volume of 246,900 shares, the short-interest ratio is presently 10.9 days. Currently, 28.0% of the company's stock are short sold. View Axonics Modulation Technologies' Current Options Chain.

Who are some of Axonics Modulation Technologies' key competitors?

What other stocks do shareholders of Axonics Modulation Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axonics Modulation Technologies investors own include Oasis Petroleum (OAS), Intrexon (XON), Camping World (CWH), PagSeguro Digital (PAGS), US Xpress Enterprises (USX), Cyberark Software (CYBR), MEI Pharma (MEIP), Dresser-Rand Group (DRC), Achieve Life Sciences (ACHV) and Auris Medical (EARS).

Who are Axonics Modulation Technologies' key executives?

Axonics Modulation Technologies' management team includes the folowing people:
  • Mr. Raymond W. Cohen, CEO & Director (Age 60)
  • Mr. Danny L. Dearen, Pres & CFO (Age 56)
  • Dr. Karen L. Noblett M.D., M.A.S., Chief Medical Officer (Age 56)
  • Mr. Rinda K. Sama, Chief Operating Officer (Age 40)
  • Mr. Guangqiang Jiang Ph.D., Chief Technology Officer (Age 46)

When did Axonics Modulation Technologies IPO?

(AXNX) raised $100 million in an initial public offering on Wednesday, October 31st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

How do I buy shares of Axonics Modulation Technologies?

Shares of AXNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Axonics Modulation Technologies' stock price today?

One share of AXNX stock can currently be purchased for approximately $20.44.

How big of a company is Axonics Modulation Technologies?

Axonics Modulation Technologies has a market capitalization of $582.95 million and generates $710,000.00 in revenue each year. The company earns $-32,480,000.00 in net income (profit) each year or ($4.64) on an earnings per share basis. Axonics Modulation Technologies employs 87 workers across the globe.View Additional Information About Axonics Modulation Technologies.

What is Axonics Modulation Technologies' official website?

The official website for Axonics Modulation Technologies is http://www.axonicsmodulation.com/.

How can I contact Axonics Modulation Technologies?

Axonics Modulation Technologies' mailing address is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. The company can be reached via phone at 949-396-6322.


MarketBeat Community Rating for Axonics Modulation Technologies (NASDAQ AXNX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  49 (Thanks for Voting!)
Underperform Votes:  50 (Thanks for Voting!)
Total Votes:  99
MarketBeat's community ratings are surveys of what our community members think about Axonics Modulation Technologies and other stocks. Vote "Outperform" if you believe AXNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/21/2019 by MarketBeat.com Staff

Featured Article: Compound Interest

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel